announces new 2014 grants, investing over $3.1 million to accelerate research

December 23, 2014

(Cincinnati, OH) The International Rett Syndrome Foundation - now doing business as - announces today that twelve (12) new grants were added to their research portfolio for a $1.2M investment, bringing the total 2014 research spend over $3.1M. is the leading private funder of Rett research, with more than $35 million invested to date.'s strategy is to accelerate research toward new treatments for Rett syndrome by investing in basic, translational, and clinical research grants, which are vetted through a rigorous process of peer review by members of's Scientific Review Board (SRB). Those applications that have the highest scientific and programmatic merit are recommended to the Board of Directors for final funding decisions.

Two of the grants are funded by the Translational Research Program which funds early and late stage translational research to treat and reverse Rett syndrome (RTT). welcomes five new fellows to the Mentored Training Fellowship Program, which funds talented young post-doctoral researchers and aims to help them establish careers in Rett research.

Lastly, five grants from the Basic Research Program will fund investigators working to make new discoveries that will lead to a better understanding of the pathology of Rett syndrome and new avenues to treat the disorder.

With these new 2014 projects, continues to cover the spectrum of Rett syndrome research, in hopes of accelerating research from basic discovery, where ideas are made, to translating them into medicines for future clinical testing and treatments. These research grants are not restricted by geographic boundaries, and two new awards were given to researchers from Italy and the United Kingdom. also announces that they will partner with the International Foundation for CDKL5 Research (IFCR) once again, to cost-share one of the newly awarded fellowships. With this continuing collaboration, both organizations can "share in funding this common endeavor that may have important implications for both CDKL5 and MECP2." said Katheryn Elibri Frame, DO, President and Co-founder of IFCR.'s Chief Science Officer, Steve Kaminsky, PhD, comments on the research strategy: "This year we had a great response to our Call for Proposals, and through the peer review process and programmatic planning, we have identified 12 research projects that will develop new ideas we hope to be translated to medicines. With the completion of two clinical trials and several others still underway, these are truly exciting times for the Rett community. These 12 new research projects add to our research investments, and we are hopeful that they build upon our portfolio and research strategy. We appreciate all of your support and look forward to this research adding to the growing knowledge base that will aid in correcting Rett biology."

New Fall 2014 Awards

HeART HeART Awards - Scout Program Mentored Training Fellowships Basic Research Grants Supplemental Funding to Current Projects For the complete list of 2014 awards, please visit
About is accelerating research for treatments and a cure for Rett syndrome. As the world's leading private funder of Rett research, we have funded more than $35 million in peer-reviewed research grants and programs to date. We are a 501(c)3 organization, earning Charity Navigator's most prestigious 4-star rating. We empower families to make a difference. Visit to learn more, or call (800) 818-7388 (RETT).

About Rett syndrome

Rett syndrome is a rare non-inherited genetic postnatal neurological disorder that occurs almost exclusively in girls and leads to lifelong impairments, affecting nearly every aspect of child's life: their ability to speak, walk, eat is effected, seizures develop and scoliosis occurs, and many develop irregular breathing patterns. Those diagnosed with Rett syndrome require maximum assistance with basic daily activities. The hallmark sign of Rett syndrome is near constant repetitive hand movements. Cognitive assessment in children with Rett syndrome is complicated, but they understand far more than they can communicate to us, evidenced by their bright and attentive eyes, and their ability to express a wide spectrum of moods and emotions.

International Rett Syndrome Foundation

Related Rett Syndrome Articles from Brightsurf:

Proteins -- and labs -- coming together to prevent Rett syndrome
Two labs investigated whether the disruption of one protein's condensate-forming ability contributes to Rett syndrome.

Genetic editing milestone in mouse model of Rett Syndrome
A genomic error that causes Rett Syndrome, a serious lifelong neurological disorder, can be corrected in the brains of mice by rewriting the genetic instructions carried by the RNA.

Yale researchers find potential treatment for Rett Syndrome
An experimental cancer drug can extend the life of mice with Rett Syndrome, a devastating genetic disorder that afflicts about one of every 10,000 to 15,000 girls within 6 to 18 months after birth, Yale researchers report June 10 in the journal Molecular Cell.

Research team investigates abnormal neuron activity in Rett syndrome
Research by Billy Lau, a postdoctoral researcher working with Assistant Professor Keerthi Krishnan at the University of Tennessee, Knoxville, examines the time during which an adult female mouse first learns to recognize and respond to the distress cries of young mouse pups as an opportunity for the brain to rewire and learn again.

A dietary supplement improves skills of an atypical Rett syndrome patient
Administration of the amino acid L-serine, a dietary supplement, contributes to the improvement of the communicative and motor skills of a patient with a mutation that alters glutamate receptors.

A new drug shows preclinical efficacy in Rett syndrome
A new article published in the Cell Reports describes how a new drug is able to reduce the symptoms and activate the dormant neurons characteristic of Rett Syndrome in preclinical models.

X chromosome reactivation could treat Rett syndrome, other X-linked disorders
A study from a team of Massachusetts General Hospital investigators points toward a potential strategy for treating X-linked disorders -- those caused by mutations in the X chromosome -- in females.

Discovery fuels hope for Rett syndrome treatment
Vanderbilt University researchers have relieved symptoms of Rett syndrome in a mouse model with a small molecule that works like the dimmer switch in an electrical circuit.

Drug improves brain performance in Rett syndrome mice
A brain penetrant drug -- a small-molecule mimetic of BDNF, or brain derived neurotrophic factor -- is able to improve brain performance in Rett syndrome mice -- specifically synaptic plasticity in the hippocampus and object location memory.

Small-molecule therapeutic boosts spatial memory and motor function in Rett syndrome mice
Rett syndrome is a neurological disorder affecting learning and development, caused by a mutation in the MECP2 gene triggering decreased levels of brain-derived neurotrophic factor (BDNF).

Read More: Rett Syndrome News and Rett Syndrome Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to